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The current epidemic of a new coronavirus disease 
(COVID-19), caused by a novel coronavirus (2019-nCoV), 
recently officially named severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), has reopened the issue 
of the role and importance of coronaviruses in human pa-
thology (1-5). This epidemic definitively confirms that this 
heretofore relatively harmless family of viruses, Coronaviri-
dae, includes major pathogens of epidemic potential. The 
COVID-19 epidemic has clearly demonstrated the power 
of infectious diseases, which have been responsible for 
many devastating epidemics throughout history. The epi-
demiological potential of emerging infectious diseases, es-
pecially zoonoses, is affected by numerous environmental, 
epidemiological, social, and economic factors (6,7). Emerg-
ing zoonoses pose both epidemiological and clinical chal-
lenges to health care professionals.
Since the 1960s, coronaviruses have caused a wide vari-
ety of human and animal diseases. In humans, they cause 
up to a third of all community-acquired upper respirato-
ry tract infections, such as the common cold, pharyngitis, 
and otitis media. However, more severe forms of bronchi-
olitis, exacerbations of asthma, and pneumonia in children 
and adults have also been described, sometimes with fatal 
outcomes in infants, the elderly, and the immunocompro-
mised. Some coronaviruses are associated with gastroin-
testinal disease in children. Sporadic infections of the cen-
tral nervous system have also been reported, although the 
role of coronaviruses in infections outside the respiratory 
tract has not been completely clarified (8).
PRevIous ePIdeMIcs cAused by coRonAvIRuses
Most coronaviruses are adapted to their hosts, whether an-
imal or human, although cases of possible animal-to-hu-
man transmission and adaptation have been described in 
the past two decades, causing two epidemics.
The first such outbreak originated in Guangdong, a south-
ern province of the People’s Republic of China, in mid-
November of 2002. The disease was named severe acute 
respiratory syndrome (SARS). The cause was shown to be 
a novel coronavirus (SARS-CoV), an animal virus that had 
crossed the species barrier and infected humans. The most 
likely reservoir was bats, with evidence that the virus was 
transmitted to a human through an intermediate host, 
probably a palm civet or raccoon dog (8,9).
In less than a year, SARS-CoV infected 8098 people in 26 
countries, of whom 774 died (10,11). Approximately 25% 
of the patients developed organ failure, most often acute 
respiratory distress syndrome (ARDS), requiring admission 
to an intensive care unit (ICU), while the case fatality rate 
(CFR) was 9.6%. However, in elderly patients (>60 years), 
the CFR was over 40%. Poor outcomes were seen in pa-
tients with certain comorbidities (diabetes mellitus and 
hepatitis B virus infection), patients with atypical symp-
toms, and those with elevated lactic acid dehydrogenase 
(LDH) values on admission. Interestingly, the course of the 
disease was biphasic in 80% of the cases, especially those 
with severe clinical profiles, suggesting that immunologi-
cal mechanisms, rather than only the direct action of SARS-
CoV, are responsible for some of the complications and fa-
tal outcomes (8,9).
Approximately 20% of the reported cases during this epi-
demic were health care workers. Therefore, in addition to 
persons exposed to animal sources and infected fam-
ily members, health care workers were among the 
most heavily exposed and vulnerable individuals 
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(9,10). During 2004, three minor outbreaks were described 
among laboratory personnel engaged in coronavirus re-
search. Although several secondary cases, owing to close 
personal contact with infected patients, were described, 
there was no further spread of the epidemic. It is not clear 
how the SARS-CoV eventually disappeared and if it still cir-
culates in nature among animal reservoirs. Despite ongo-
ing surveillance, there have been no reports of SARS in hu-
mans worldwide since mid-2004 (11).
In the summer of 2012, another epidemic caused by a nov-
el coronavirus broke out in the Middle East. The disease, 
often complicated with respiratory and renal failure, was 
called Middle East respiratory syndrome (MERS), while the 
novel coronavirus causing it was called Middle East respira-
tory syndrome coronavirus (MERS-CoV). Although a coro-
navirus, it is not related to the coronaviruses previously de-
scribed as human pathogens. However, it is closely related 
to a coronavirus isolated from dromedary camels and bats, 
which are considered the primary reservoirs, albeit not the 
only ones (8,12).
From 2012 to the end of January 2020, over 2500 laborato-
ry-confirmed MERS cases, including 866 associated deaths, 
were reported worldwide in 27 countries (13). The largest 
number of such cases has been reported among the el-
derly, diabetics, and patients with chronic diseases of the 
heart, lungs, and kidneys. Over 80% of the patients required 
admission to the ICU, most often due to the development 
of ARDS, respiratory insufficiency requiring mechanical 
ventilation, acute kidney injury, or shock. The CFR is around 
35%, and even 75% in patients >60 years of age. However, 
MERS-CoV, unlike its predecessor SARS-CoV, did not disap-
pear, but still circulates among animal and human popula-
tions, occasionally causing outbreaks, either in connection 
with exposure to camels or infected persons (12).
Overall, 19.1% of all MERS cases have been among health 
care workers, and more than half of all laboratory-con-
firmed secondary cases were transmitted from human 
to human in health care settings, at least in part due to 
shortcomings in infection prevention and control (12,13). 
Post-exposure prophylaxis with ribavirin and lopinavir/rito-
navir decreased the MERS-CoV risk in health care workers 
by 40% (14).
THe eMeRGence oF covId-19 cAused by sARs-cov-2
In mid-December of 2019, a pneumonia outbreak 
erupted once again in China, in the city of Wuhan, 
the province of Hube (1). The outbreak spread during the 
next two months throughout the country, with currently 
over 80 000 cases and more than 2400 fatal outcomes (CFR 
2.5%), according to official reports. Exported cases have 
been reported in 30 countries throughout the world, with 
over 2400 registered cases, of which 276 are in Europe. On 
February 25, the first case of COVID-19 was confirmed in 
Zagreb, Croatia, and was linked to the current outbreak in 
the Lombardy and Veneto regions of northern Italy (15).
The case definition was first established on January 10 and 
modified over time, taking into account both the virus epi-
demiology and clinical presentation. The clinical criteria 
were expanded on February 4 to include any lower acute 
respiratory diseases, and the epidemiological criterion was 
extended to the whole of China, with the possibility of ex-
pansion to some surrounding countries (16,17).
At the early stage of the outbreak, patients’ full-length ge-
nome sequences were identified, showing that the virus 
shares 79.5% sequence identity with SARS-CoV. Further-
more, 96% of its whole genome is identical to bat corona-
virus. It was also shown that this virus uses the same cell 
entry receptor, ACE2, as SARS-CoV (18).
The full clinical spectrum of COVID-19 ranges from as-
ymptomatic cases, mild cases that do not require hospi-
talization, to severe cases that require hospitalization and 
ICU treatment, and those with fatal outcomes. Most cases 
were classified as mild (81%), 14% as severe, and 5% as 
critical (ie, respiratory failure, septic shock, and/or multiple 
organ dysfunction or failure). The overall CFR was 2.3%, 
while the rate in patients with comorbidities was consid-
erably higher – 10.5% for cardiovascular disease, 7.3% for 
diabetes, 6.3% for chronic respiratory diseases, 6.0% for 
hypertension, and 5.6% for cancer. The CFR in critical pa-
tients was as high as 49.0% (4).
It is still not clear which factors contribute to the risk of 
transmitting the infection, especially by persons who are 
in the incubation stage or asymptomatic, as well as which 
factors contribute to the severity of the disease and fatal 
outcome. Evidence from various types of additional stud-
ies is needed to control the epidemic (19).
However, it is certain that the binding of the virus to the 
ACE 2 receptor can induce certain immunoreactions, and 
the receptor diversity between humans and animal spe-
cies designated as SARS-CoV-2 reservoirs further increases 
the complexity of COVID-19 immunopathogenicity (20). 
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Recently, a diagnostic RT-PCR assay for the detection of 
SARS-CoV-19 has been developed using synthetic nucleic 
acid technology, despite the lack of virus isolates and clini-
cal samples, owing to its close relation to SARS. Additional 
diagnostic tests are in the pipeline, some of which are likely 
to become commercially available soon (21).
Currently, randomized controlled trials have not shown 
any specific antiviral treatment to be effective for COVID-
19. Therefore, treatment is based on symptomatic and sup-
portive care, with intensive care measures for the most se-
vere cases (22). However, many forms of specific treatment 
are being tried, with various results, such as with remdesiv-
ir, lopinavir/ritonavir, chloroquine phosphate, convalescent 
plasma from patients who have recovered from COVID-19, 
and others (23-26).
No vaccine is currently available, but researchers and vac-
cine manufacturers have been attempting to develop the 
best option for COVID-19 prevention. So far, the basic target 
molecule for the production of a vaccine, as well as thera-
peutic antibodies, is the CoV spike (S) glycoprotein (27,28).
The spread of the epidemic can only be contained and 
SARS-CoV-2 transmission in hospitals by strict compliance 
with infection prevention and control measures (contact, 
droplet, and airborne precautions) (22,29). During the cur-
rent epidemic, health care workers have been at an in-
creased risk of contracting the disease and consequent 
fatal outcome owing to direct exposure to patients. Early 
reports from the beginning of the epidemic indicated that 
a large proportion of the patients had contracted the in-
fection in a health care facility (as high as 41%), and that 
health care workers constituted a large proportion of these 
cases (as high as 29%). However, the largest study to date 
on more than 72 000 patients from China has shown that 
health care workers make up 3.8% of the patients. In this 
study, although the overall CFR was 2.3%, among health 
care workers it was only 0.3%. In China, the number of se-
vere or critical cases among health care workers has de-
clined overall, from 45.0% in early January to 8.7% in early 
February (4). This poses numerous psychological and ethi-
cal questions about health care workers’ role in the spread, 
eventual arrest, and possible consequences of epidem-
ics. For example, during the 2014-2016 Ebola virus disease 
epidemic in Africa, health care workers risked their lives in 
order to perform life-saving invasive procedures (intrave-
nous indwelling, hemodialysis, reanimation procedures, 
mechanical ventilation), and suffered high stress and fa-
tigue levels, which may have prevented them from prac-
ticing optimal safety measures, sometimes with dire con-
sequences (30).
A lesson FoR THe FuTuRe
This third coronavirus epidemic, caused by the highly 
pathogenic SARS-CoV-2, underscores the need for the on-
going surveillance of infectious disease trends throughout 
the world. The examples of pandemic influenza, avian in-
fluenza, but also the three epidemics caused by the novel 
coronaviruses, indicate that respiratory infections are a ma-
jor threat to humanity. Although Ebola virus disease and 
avian influenza are far more contagious and influenza cur-
rently has a greater epidemic potential, each of the three 
novel coronaviruses require urgent epidemiologic surveil-
lance. Many infectious diseases, such as diphtheria, mea-
sles, and whooping cough, have been largely or complete-
ly eradicated or controlled through the use of vaccines. It 
is hoped that developments in vaccinology and antiviral 
treatment, as well as new preventive measures, will ulti-
mately vanquish this and other potential threats from in-
fectious diseases in the future.
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